Increasing your semaglutide dose: what actually happens and when

Why does semaglutide start so low before increasing?

A question our prescribers hear most weeks is why 0.25mg (a dose too small to produce meaningful weight loss in most people) is where treatment begins. The answer is straightforward: your gut needs time to adapt to a GLP-1 medicine. Semaglutide slows gastric emptying and suppresses appetite through the GLP-1 receptor; introduce too much of that effect at once and nausea and vomiting become hard to tolerate.

Starting at 0.25mg for the first four weeks, then moving to 0.5mg, then 1.0mg, then 1.7mg, and finally 2.4mg as the standard maintenance dose gives your system a chance to adjust at each level before the next step. The STEP 1 trial, published in the New England Journal of Medicine, used exactly this titration pathway and recorded an average weight reduction of around 15% over 68 weeks at 2.4mg. That result came from patients who spent most of the trial at the higher maintenance doses, not at the starter levels.

Skipping a step or titrating faster is not recommended. Your prescriber will only move you up when you have tolerated the current dose for the required period. If side effects at a given level are significant, staying at that dose for longer (or pausing the increase) is a clinical decision, not a failure.

What should you expect when you increase your dose?

Each increase typically brings a short recalibration period. Nausea is the most commonly reported effect in the days following a step up; others include loose stools, constipation, reduced appetite beyond what you had at the previous dose, fatigue, and occasional headache. These effects are usually most noticeable in the first few days and often settle by the end of the first two weeks at the new strength.

The NHS semaglutide medicines page lists these gastrointestinal effects as common and notes that they tend to be temporary. Eating smaller meals, staying well hydrated, and avoiding very fatty or heavily spiced food during the adjustment window helps most people through the peak. There is a separate, more detailed look at what to expect on the side effects of increasing your Wegovy dose page if you want to go deeper.

If symptoms are severe (particularly persistent abdominal pain that radiates to the back) seek medical attention promptly. The MHRA highlighted acute pancreatitis as a known though infrequent risk associated with GLP-1 medicines in its January 2026 Drug Safety Update; that symptom pattern is the one to act on without delay.

Does increasing the dose actually increase weight loss?

In clinical terms, yes — but the relationship is not perfectly linear, and individual response varies considerably. The lower doses in the titration ladder do contribute to appetite suppression, but the full therapeutic effect of semaglutide for weight management is most evident at the 1.7mg and 2.4mg maintenance levels. Patients who reach and sustain 2.4mg generally see the largest reductions in body weight over the course of treatment.

The 2026 MHRA approval of a 7.2mg dose adds a further step for patients who are already established on 2.4mg. Early data reported around 20.7% average weight loss over 72 weeks at this higher dose, which narrows the gap with tirzepatide results considerably. Whether the 7.2mg dose is right for a particular patient depends on their response at 2.4mg and a clinical review, it is not automatically the next step for everyone. You can read more about how the two medicines compare across the full range of dose levels on the does increasing Wegovy dose increase weight loss page.

The practical upshot: staying on the programme long enough to reach your maintenance dose, and tolerating increases rather than dropping back repeatedly, is where the strongest results come from. That is easier said than done, which is part of why aftercare and regular prescriber contact matter.

Who decides when to increase, and what does the review involve?

Your prescriber makes the call. A semaglutide dose increase is not something you adjust yourself based on how you feel; the timing and appropriateness of each step are assessed clinically. At num, every repeat order triggers a clinical review before anything is dispensed, a real prescriber reads your update, not an automated system. That review looks at how you have tolerated the current dose, any side effects you have reported, and whether a step up is appropriate at this point.

For patients transferring from another provider, evidence of current dose and recent clinical history is required before any increase is considered. This applies to the semaglutide dosage increase process generally and is not unique to num, it reflects standard GPhC-registered pharmacy practice. If you have questions about where you are in your titration or whether a step up is due, our guide to increasing your dose of Wegovy walks through exactly how each step is assessed, and our prescribers are available seven days a week through aftercare. Separately, if you have come across higher or more frequent amounts being discussed in fitness circles, the semaglutide bodybuilding dosage page explains why those approaches differ from the clinically approved titration schedule and what the evidence actually shows. The full Wegovy dose guide covers the schedule in detail.

If you are weighing up whether to start treatment or want to understand more about the full Wegovy programme before committing, speak to our prescribers through a free consultation, same-day clinical review, no waiting list, and next-working-day delivery once approved.